Sendero Wealth Management LLC Has $4.54 Million Position in DexCom, Inc. $DXCM

Sendero Wealth Management LLC grew its position in DexCom, Inc. (NASDAQ:DXCM) by 85.6% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 67,423 shares of the medical device company’s stock after purchasing an additional 31,094 shares during the period. Sendero Wealth Management LLC’s holdings in DexCom were worth $4,537,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in DXCM. GAMMA Investing LLC lifted its holdings in DexCom by 2.5% during the 3rd quarter. GAMMA Investing LLC now owns 7,043 shares of the medical device company’s stock valued at $474,000 after purchasing an additional 169 shares during the last quarter. Meiji Yasuda Asset Management Co Ltd. increased its holdings in shares of DexCom by 3.2% during the first quarter. Meiji Yasuda Asset Management Co Ltd. now owns 6,019 shares of the medical device company’s stock worth $411,000 after buying an additional 187 shares in the last quarter. Integrated Wealth Concepts LLC increased its holdings in shares of DexCom by 6.3% during the first quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after buying an additional 196 shares in the last quarter. STF Management LP raised its stake in shares of DexCom by 5.5% in the second quarter. STF Management LP now owns 4,041 shares of the medical device company’s stock valued at $353,000 after acquiring an additional 211 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB boosted its holdings in shares of DexCom by 23.9% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 1,125 shares of the medical device company’s stock worth $98,000 after acquiring an additional 217 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

DexCom Price Performance

Shares of DXCM stock opened at $65.75 on Thursday. The stock has a 50-day moving average price of $63.96 and a 200 day moving average price of $74.03. The company has a quick ratio of 1.38, a current ratio of 1.56 and a debt-to-equity ratio of 0.45. The firm has a market cap of $25.64 billion, a price-to-earnings ratio of 36.53, a PEG ratio of 1.42 and a beta of 1.51. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $93.25.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.04. The company had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.18 billion. DexCom had a net margin of 15.96% and a return on equity of 30.65%. The company’s revenue was up 21.6% compared to the same quarter last year. During the same period in the prior year, the company posted $0.45 EPS. Research analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Buying and Selling at DexCom

In other DexCom news, COO Jacob Steven Leach bought 18,200 shares of the stock in a transaction on Monday, November 10th. The stock was purchased at an average price of $55.04 per share, with a total value of $1,001,728.00. Following the acquisition, the chief operating officer owned 331,697 shares of the company’s stock, valued at approximately $18,256,602.88. The trade was a 5.81% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Richard Alexander Collins sold 3,948 shares of the company’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $55.17, for a total transaction of $217,811.16. Following the sale, the director owned 37,994 shares of the company’s stock, valued at $2,096,128.98. The trade was a 9.41% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 7,866 shares of company stock valued at $448,177. 0.32% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on DXCM. Citigroup reaffirmed a “buy” rating and set a $77.00 price target (up from $75.00) on shares of DexCom in a report on Thursday, December 11th. Robert W. Baird set a $82.00 target price on DexCom in a research note on Friday, October 31st. Oppenheimer cut DexCom from an “outperform” rating to a “market perform” rating in a report on Monday, September 8th. Morgan Stanley raised shares of DexCom from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $63.00 to $75.00 in a report on Tuesday, December 2nd. Finally, Argus lowered their price objective on shares of DexCom from $100.00 to $90.00 and set a “buy” rating for the company in a research report on Friday, November 7th. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, DexCom presently has an average rating of “Moderate Buy” and a consensus target price of $86.61.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.